Overview

Controlled Study of Post-transplant Azacitidine for Prevention of Acute Myelogenous Leukemia and Myelodysplastic Syndrome Relapse (VZ-AML-PI-0129)

Status:
Completed

Trial end date:
2018-08-20

Target enrollment:

Participant gender:

Summary

The goal of this clinical research study is to learn if Vidaza (azacitidine) will help to control the disease in patients with AML, CMML, or MDS after an allogeneic (donor) stem cell transplant. The safety of this drug will also be studied.

Phase:

Phase 3

Details

Lead Sponsor:

M.D. Anderson Cancer Center

Collaborator:

Celgene

Treatments:

Azacitidine